复星医药(02196.HK) 公布,控股子公司桂林南药股份就注射用硫酸多黏菌素B,以及上海朝晖药业就盐酸拉贝洛尔注射液的药品注册上市申请已分别获国家药品监督管理局受理。(de/d)(港股报价延迟最少十五分钟。沽空资料截至 2025-02-10 16:25。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.